Trade Genfit SA - GNFTfr CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.08 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.019349% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.002873% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | EUR | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | France | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.32 |
| Open | 3.31 |
| 1-Year Change | 2.16% |
| Day's Range | 3.29 - 3.35 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 3.29 | 0.03 | 0.92% | 3.26 | 3.35 | 3.26 |
| Jan 16, 2025 | 3.32 | 0.07 | 2.15% | 3.25 | 3.37 | 3.25 |
| Jan 15, 2025 | 3.29 | 0.04 | 1.23% | 3.25 | 3.32 | 3.25 |
| Jan 14, 2025 | 3.25 | -0.03 | -0.91% | 3.28 | 3.37 | 3.25 |
| Jan 13, 2025 | 3.30 | -0.05 | -1.49% | 3.35 | 3.38 | 3.30 |
| Jan 10, 2025 | 3.41 | -0.07 | -2.01% | 3.48 | 3.57 | 3.35 |
| Jan 9, 2025 | 3.42 | 0.02 | 0.59% | 3.40 | 3.49 | 3.37 |
| Jan 8, 2025 | 3.42 | -0.08 | -2.29% | 3.50 | 3.51 | 3.42 |
| Jan 7, 2025 | 3.46 | -0.09 | -2.54% | 3.55 | 3.60 | 3.46 |
| Jan 6, 2025 | 3.53 | 0.02 | 0.57% | 3.51 | 3.61 | 3.51 |
| Jan 3, 2025 | 3.57 | -0.01 | -0.28% | 3.58 | 3.65 | 3.53 |
| Jan 2, 2025 | 3.64 | 0.19 | 5.51% | 3.45 | 3.64 | 3.45 |
| Dec 31, 2024 | 3.52 | 0.12 | 3.53% | 3.40 | 3.52 | 3.40 |
| Dec 30, 2024 | 3.44 | -0.05 | -1.43% | 3.49 | 3.55 | 3.44 |
| Dec 27, 2024 | 3.51 | 0.11 | 3.24% | 3.40 | 3.56 | 3.40 |
| Dec 24, 2024 | 3.45 | 0.02 | 0.58% | 3.43 | 3.47 | 3.43 |
| Dec 23, 2024 | 3.40 | -0.04 | -1.16% | 3.44 | 3.46 | 3.38 |
| Dec 20, 2024 | 3.38 | -0.02 | -0.59% | 3.40 | 3.46 | 3.37 |
| Dec 19, 2024 | 3.48 | -0.04 | -1.14% | 3.52 | 3.62 | 3.41 |
| Dec 18, 2024 | 3.49 | 0.15 | 4.49% | 3.34 | 3.53 | 3.34 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Genfit Company profile
About Genfit SA
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Financial summary
BRIEF: For the six months ended 30 June 2021, Genfit SA revenues decreased 42% to EUR3.4M. Net income totaled EUR9.1M vs. loss of EUR53M. Revenues reflect Public Financing of research expenditure decrease of 38% to EUR3.2M, Other Operating Income decrease of 66% to EUR174K, Revenue decrease of 91% to EUR11K. Net Income reflects R&D Subcontractors decrease of 38% to EUR15M (expense).
Equity composition
01/2014, Rights Issue, 1 new share for every 33 shares held @ EUR6.98 (Factor: 1.00937).10/2016, Rights Issue, 1 new share for every 9 shares held @ EUR14.3 (Factor: 1.09242).
| Industry: | Biotechnology & Medical Research (NEC) |
Parc Eurasanté 885 avenue Eugène Avinée
LOOS
HAUTS-DE-FRANCE 59120
FR
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com